(Q41678598)

7 October 2017

1 reference

title

A comparative approach to topical cyclosporine therapy (English)

1 reference

7 October 2017

1 reference

Williams DL

1

1 reference

7 October 2017

publication date

1 January 1997

1 reference

7 October 2017

1 reference

7 October 2017

volume

11 ( Pt 4)

1 reference

7 October 2017

page(s)

453-464

1 reference

https://scigraph.springernature.com/pub.10.1038/eye.1997.126

7 October 2017

exact match

0 references

cites work

Biological effects of cyclosporin A: A new antilymphocytic agent

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

Cyclosporin A in patients receiving renal allografts from cadaver donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

Factors associated with early remission of type I diabetes in children treated with cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

An open, controlled, randomized comparison of cyclosporine and azathioprine in the treatment of rheumatoid arthritis: a preliminary report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

Cyclosporin a. Inhibition of experimental autoimmune uveitis in Lewis rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

A placebo-controlled blind trial of cyclosporin-A in prevention of corneal graft rejection in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

FK506 and cyclosporin, molecular probes for studying intracellular signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

Cyclosporin A inhibits activation-induced cell death in T-cell hybridomas and thymocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

Reactive lymphocytes in lacrimal gland and vasculitic renal lesions of autoimmune MRL/lpr mice express L3T4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

Effect of cyclosporin A (CyA) on the immunopathological lesion of the labial minor salivary glands from patients with Sjögren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

Penetration of 2% cyclosporin eyedrops into human aqueous humour

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

Cyclosporin A: tissue levels following topical and systemic administration to rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

Local cyclosporine therapy for experimental autoimmune uveitis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

Prolonged survival of allogeneic corneal grafts in rabbits treated with topically applied cyclosporin A: systemic absorption and local immunosuppressive effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

Effect of cyclosporin A on the survival of corneal grafts in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

Treatment of Mooren's ulcer with cyclosporin A: report of three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

Human conjunctival mast cells: distribution of MCT and MCTC in vernal conjunctivitis and giant papillary conjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

Prophylactic Topical Cyclosporine in Experimental Herpetic Stromal Keratitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

Cyclosporin A inhibits Coccidioides immitis in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

7 January 2021

Treatment of intraocular inflammatory disease with cyclosporin A

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

7 January 2021

Immunological analysis and treatment of Mooren's ulcer with cyclosporin A applied topically

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

7 January 2021

Immunohistologic findings and results of treatment with cyclosporine in ligneous conjunctivitis

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

7 January 2021

Topical cyclosporine therapy for ulcerative keratitis associated with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

7 January 2021

Topical cyclosporin A in the treatment of anterior segment inflammatory disease

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

7 January 2021

The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

7 January 2021

Does the binding of cyclosporine to calmodulin result in immunosuppression?

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

7 January 2021

FK-506 and cyclosporin a: Selective inhibition of calcium ionophore-induced polymorphonuclear leukocyte degranulation

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

7 January 2021

The immunoarchitecture of the normal human lacrimal gland. Relevancy for understanding pathologic conditions

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

7 January 2021

Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporine eye drops

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

7 January 2021

Bilateral keratoconjunctivitis sicca in a horse

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

7 January 2021

Prolactin receptors on human lymphocytes and their modulation by cyclosporine

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

7 January 2021

Rapamycin, FK506 and cyclosporin A inhibit human prolactin gene expression

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

7 January 2021

Penetration of topical cyclosporine into the rabbit cornea, aqueous humor, and serum

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

7 January 2021

Ocular absorption of cyclosporine A from liposomes incorporated into collagen shields

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

7 January 2021

Clinical types of corneal transplant rejection. Their manifestations, frequency, preoperative correlates, and treatment

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

7 January 2021

Systemic cyclosporine in high-risk keratoplasty. Short- versus long-term therapy

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

7 January 2021

Cyclosporin A treatment in two cases of corneal peripheral melting syndrome

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

7 January 2021

Treatment of canine nictitans plasmacytic conjunctivitis with 0.2 per cent cyclosporin ointment

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

7 January 2021

Cyclosporin-responsive keratoconjunctivitis in the cat and horse

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

7 January 2021

Topical Cyclosporine in Vernal Keratoconjunctivitis

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

7 January 2021

Influence of topically applied cyclosporine A in olive oil on corneal epithelium permeability.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

7 January 2021

Diagnostic tests in the Sicca syndrome

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

7 January 2021

Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

7 January 2021

Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren's syndrome

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1997.126

7 January 2021

Identifiers

DOI

10.1038/EYE.1997.126

1 reference

Dimensions Publication ID

7 October 2017

1016853437

0 references

1 reference